US-based Spectrum Pharmaceuticals has begun a Phase II clinical trial of its new pan-HER inhibitor, Poziotinib, for patients with HER2-positive metastatic breast cancer.

The open-label trial will involve around 70 patients who have failed at least two prior HER2-directed therapies.

The company noted that Poziotinib has shown a 60% response rate in Phase I patients with breast cancer who had previously failed multiple lines of treatment, including the HER2-directed therapies.

Poziotinib irreversibly blocks signalling through the epidermal growth factor receptor (EGFR, HER) family of tyrosine-kinase receptors, including HER1, HER2, and HER4.

"We believe Poziotinib has the potential to be the best-in-class pan-HER inhibitor."

It also blocks HER receptor mutations, which inhibits the proliferation of tumour cells that overexpress these receptors.

Spectrum Pharmaceuticals chairman and chief executive officer Rajesh Shrotriya said: "We believe Poziotinib has the potential to be the best-in-class pan-HER inhibitor.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

"The US Phase II trial was designed on learnings from Hanmi’s Phase I studies, as well as the ongoing Phase II breast cancer trial in Korea.

"The target market for HER2-positive agents is large, and we are encouraged by early data showing that Poziotinib could potentially be another treatment option for patients."

It is reported that mutations or overexpression / amplification of EGFR family receptors have been associated with a number of different cancers, including non-small cell lung cancer (NSCLC), breast cancer and gastric cancer.

At present, poziotinib is being evaluated by Hanmi in several mid-stage trials in different solid tumour indications, including HER2-positive breast cancer.